Tripathy Manoj K, McManamy Mary E M, Burch Brandon D, Archin Nancie M, Margolis David M
Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
J Virol. 2015 Aug;89(16):8392-405. doi: 10.1128/JVI.00572-15. Epub 2015 Jun 3.
Histone methyltransferase inhibitors (HMTis) and histone deacetylase inhibitors (HDACis) are reported to synergistically induce the expression of latent human immunodeficiency virus type 1 (HIV-1), but studies have largely been performed with cell lines. As specific and potent HMTis directed at EZH1 (enhancer of zeste 2 Polycomb repressive complex 2 subunit 1)/EZH2 are now in human testing, we wished to rigorously test such an inhibitor in a primary resting T-cell model of HIV latency. We found that GSK343, a potent and selective EZH2/EZH1 inhibitor, reduced trimethylation of histone 3 at lysine 27 (H3K27) of the HIV provirus in resting cells. Remarkably, this epigenetic change was not associated with increased proviral expression in latently infected resting cells. However, following the reduction in H3K27 at the HIV long terminal repeat (LTR), subsequent exposure to the HDACi suberoylanilide hydroxamic acid or vorinostat (VOR) resulted in increases in HIV gag RNA and HIV p24 antigen production that were up to 2.5-fold greater than those induced by VOR alone. Therefore, in primary resting CD4(+) T cells, true mechanistic synergy in the reversal of HIV latency may be achieved by the combination of HMTis and HDACis. Although other cellular effects of EZH2 inhibition may contribute to the sensitization of the HIV LTR to subsequent exposure to VOR, and to increase viral antigen production, this synergistic effect is directly associated with H3K27 demethylation at nucleosome 1 (Nuc-1). Based upon our findings, the combination of HMTis and HDACis should be considered for testing in animal models or clinical trials.
Demethylation of H3K27 mediated by the histone methyltransferase inhibitor GSK343 in primary resting T cells is slow, occurring over 96 h, but by itself does not result in a significant upregulation of cell-associated HIV RNA expression or viral antigen production. However, following H3K27 demethylation, latent viral expression within infected primary resting CD4(+) T cells is synergistically increased upon exposure to the histone deacetylase inhibitor vorinostat. Demethylation at H3K27 sensitizes the HIV promoter to the effects of an HDACi and provides a proof-of-concept for the testing of combination epigenetic approaches to disrupt latent HIV infection, a necessary step toward the eradication of HIV infection.
据报道,组蛋白甲基转移酶抑制剂(HMTis)和组蛋白脱乙酰酶抑制剂(HDACis)可协同诱导潜伏的1型人类免疫缺陷病毒(HIV-1)表达,但相关研究大多在细胞系中进行。由于针对EZH1(zeste 2 Polycomb抑制复合物2亚基1增强子)/EZH2的特异性强效HMTis目前正在人体试验中,我们希望在HIV潜伏的原代静息T细胞模型中严格测试此类抑制剂。我们发现,强效选择性EZH2/EZH1抑制剂GSK343可降低静息细胞中HIV原病毒组蛋白3赖氨酸27位点(H3K27)的三甲基化。值得注意的是,这种表观遗传变化与潜伏感染的静息细胞中前病毒表达增加无关。然而,在HIV长末端重复序列(LTR)处H3K27减少后,随后暴露于HDACi辛二酰苯胺异羟肟酸或伏立诺他(VOR)会导致HIV gag RNA和HIV p24抗原产生增加,比单独使用VOR诱导的增加高达2.5倍。因此,在原代静息CD4(+) T细胞中,HMTis和HDACis联合使用可能在逆转HIV潜伏方面实现真正的机制协同作用。尽管抑制EZH2的其他细胞效应可能有助于使HIV LTR对随后暴露于VOR敏感,并增加病毒抗原产生,但这种协同效应与核小体1(Nuc-1)处的H3K27去甲基化直接相关。基于我们的发现,应考虑在动物模型或临床试验中测试HMTis和HDACis的联合使用。
组蛋白甲基转移酶抑制剂GSK343介导的原代静息T细胞中H3K27去甲基化过程缓慢,持续96小时,但本身不会导致细胞相关HIV RNA表达或病毒抗原产生显著上调。然而,在H3K27去甲基化后,感染的原代静息CD4(+) T细胞内潜伏病毒表达在暴露于组蛋白脱乙酰酶抑制剂伏立诺他后会协同增加。H3K27去甲基化使HIV启动子对HDACi的作用敏感,并为测试联合表观遗传方法破坏潜伏HIV感染提供了概念验证,这是根除HIV感染的必要步骤。